12/15/2025
Putting the politics of FDA aside, the panel included very big names in Urology. The experts on the panel, along those that were referenced, are very reputable physicians at the cutting edge of the contemporary science of testosterone replacement therapy. 
“Notably, the panel addressed the outdated label language—particularly the inaccurate implication that TRT increases prostate cancer risk—and reconsidering testosterone’s classification as a Schedule III controlled substance, which he says creates unnecessary barriers to patient access.”
These are important changes that will allow more responsible administration of medically supervised testosterone replacement therapy.
Be well
Be HOL
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men.